The house dust mite disease market is experiencing steady growth, driven by rising global prevalence of allergic rhinitis and asthma linked to indoor allergens. Increasing adoption of allergen-specifi ...

The house dust mite disease market is experiencing steady growth, driven by rising global prevalence of allergic rhinitis and ...

Witnessing her daughter desperately gasping for breath had become a normal, if terrifying, feature of Sophie Hafford's life.

The formulation reportedly contains ingredients such as kakadasinghi, ginger ash, licorice root, dry ginger, cinnamon, crystal ash and other herbal components. Patanjali claims that Shwasari Vati may ...

Osteoarthritis is listed as the most common type of arthritis in the UK, as stated by the NHS. This condition causes joints to become painful and stiff. While symptoms vary, many people resort to ...

People with asthma could benefit from digital tools on their phones or tablets to help them better manage their condition. National Institute for Health and Care Excellence draft guidance states that ...

We may receive a commission on purchases made from links. A tablet is a great buy if you want the portability of a smartphone in a larger form factor. Whether you need a device that will be great for ...

The FDA approved depemokimab (Exdensur) as the first ultra-long-acting biologic with twice-yearly dosing approved for patients with severe asthma with an eosinophilic phenotype, GSK announced. The ...

A new option for hard-to-control asthma: The FDA has approved Exdensur (depemokimab-ulaa) as an add-on maintenance treatment for people with severe asthma. Designed to reduce flare-ups: The injectable ...

Depemokimab-ulaa (Exdensur) is approved for severe asthma with an eosinophilic phenotype, offering protection with just two doses annually. Phase 3 trials demonstrated significant reductions in asthma ...

GSK’s depemokimab, a long-acting biologic that’s key in the British pharma’s growth plan, has won European regulatory approval for two inflammatory disease indications. The European Medicines Agency's ...